Table 2.

Results of a pooled analysis based on a five-factor model of schizophrenia25

Five PANSS factor scores	Lurasidone 40 mg/day			Lurasidone 80 mg/day			Lurasidone 120 mg/day
	Change from baseline	P	Effect size	Change from baseline	P	Effect size	Change from baseline	P	Effect size
Positive factor	−7.92	<0.001	0.35	−8.48	<0.001	0.47	−8.25	<0.001	0.42
Negative factor	−5.59	<0.001	0.41	−4.96	0.02	0.25	−5.21	0.002	0.31
Disorganized thought	−4.86	<0.001	0.40	−5.10	<0.001	0.47	−5.22	<0.001	0.50
Hostility	−2.33	<0.013	0.25	−2.58	0.002	0.33	−2.87	<0.001	0.44
Depression/anxiety	−3.14	0.002	0.31	−3.23	0.002	0.35	−3.01	0.012	0.26

Notes: Five PANSS factor scores were analysed using MMRM analysis. Adjusted effect sizes were calculated from an ANCOVA analysis (LOCF endpoint) as the between-treatment group difference in least squares mean change scores divided by the pooled standard deviation of the change scores. Reprinted from Schizophrenia Research, 117, Loebel A, Cucchiaro J, Silva R, Ogasa M, Severs J, Marder SR, Efficacy of lurasidone in schizophrenia: Results of a pooled analysis based on a 5-factor model of schizophrenia, 267, 2010, with permission from Elsevier.

Abbreviations: ANCOVA, analysis of covariance; LOCF, last observation carried forward; MMRM, mixed-effect model repeated measure; PANSS, Positive and Negative Syndrome Scale.